Tango Therapeutics, Inc.

NasdaqGM TNGX

Tango Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 6.49

Tango Therapeutics, Inc. Price to Sales Ratio (P/S) is 6.49 on January 14, 2025, a -76.65% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Tango Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 33.89 on February 02, 2024, which is 422.40% above the current Price to Sales Ratio (P/S).
Tango Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 6.49 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Tango Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 20.58.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: TNGX

Tango Therapeutics, Inc.

CEO	Dr. Barbara L. Weber M.D.
IPO Date	Sept. 3, 2020
Location	United States
Headquarters	100 Binney Street
Employees	140
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years